section name header

Pronunciation

HISS-tre-lin

Classifications

Therapeutic Classification: hormones

Pharmacologic Classification: gonadotropin releasing hormones

Indications

REMS


Action

  • Continuous administration decreases production of gonadotropins.
Therapeutic effects:
  • Suppression of testosterone production.

Pharmacokinetics

Absorption: Highly absorbed (92%) from implant. Peak absorption occurs at 12 hours, and continues over 1–year period.

Distribution: Unknown.

Protein Binding: 29%.

Metabolism/Excretion: Unknown.

Half-Life: 3.92 hours.

Time/Action Profile

( in LH, FSH, and sex-steroid levels)
ROUTEONSETPEAKDURATION
SUBQunknown12 hr52 wk





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: sweating, acne, pruritus, rash

EENT: visual disturbances

Endo: breast size, breast discharge, breast pain

Local: itching, erythema, and swelling at implantation site

Neuro: aggression, anger, anxiety, depression, dizziness, impatience, insomnia, intracranial hypertension, irritability, lethargy, malaise, SEIZURES

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Supprelin LA